F
Federico Lavorini
Researcher at University of Florence
Publications - 162
Citations - 5182
Federico Lavorini is an academic researcher from University of Florence. The author has contributed to research in topics: Inhaler & Medicine. The author has an hindex of 33, co-authored 137 publications receiving 3953 citations. Previous affiliations of Federico Lavorini include UniFi.
Papers
More filters
Journal ArticleDOI
Clinical courses and outcomes of five patients with primary lung cancer surgically treated while affected by Severe acute respiratory syndrome coronavirus 2.
Alessandro Gonfiotti,Lavinia Gatteschi,Alberto Salvicchi,Stefano Bongiolatti,Federico Lavorini,Luca Voltolini +5 more
TL;DR: Lung cancer surgery may represent a high-risk factor for developing a severe case of coronavirus disease 2019, particularly in patients with advanced stages of lung cancer.
Journal ArticleDOI
The Burden of Self-Reported Rhinitis and Associated Risk for Exacerbations with Moderate-Severe Asthma in Primary Care Patients
Vicky Kritikos,David Price,Alberto Papi,Antonio Infantino,Björn Ställberg,Dermot Ryan,Federico Lavorini,Henry Chrystyn,John Haughney,Karin Lisspers,Kevin Gruffydd-Jones,Miguel Román Rodríguez,Svein Høegh Henrichsen,Thys van der Molen,Victoria Carter,Sinthia Bosnic-Anticevich +15 more
TL;DR: A major gap is identified in the diagnosis and management of rhinitis in a cohort of people with asthma treated at GINA Step 3 and above who are managed in general practice, which is a significant factor associated with exacerbation risk.
Journal ArticleDOI
Clinical and Laboratory Follow-up After Hospitalization for COVID-19 at an Italian Tertiary Care Center.
Michele Spinicci,Iacopo Vellere,Lucia Graziani,Marta Tilli,Beatrice Borchi,Jessica Mencarini,Irene Campolmi,Leonardo Gori,Laura Rasero,Francesco Fattirolli,Iacopo Olivotto,Federico Lavorini,Niccolò Marchionni,Lorenzo Zammarchi,Alessandro Bartoloni +14 more
TL;DR: In this paper, the authors evaluated 100 postacute coronavirus disease 2019 (COVID-19) patients a median (interquartile range) of 60 (48-67) days after discharge from the Careggi University Hospital, Italy.
Journal ArticleDOI
Why We Should Target Small Airways Disease in Our Management of Chronic Obstructive Pulmonary Disease.
TL;DR: The early detection of small airway disease remains the key barrier; if detected early, treatments designed to target small airways may help reduce symptoms and allow patients to maintain their activities as mentioned in this paper.
Journal ArticleDOI
Spacers and Valved Holding Chambers-The Risk of Switching to Different Chambers.
Federico Lavorini,Celeste Barreto,Job F M van Boven,Will Carroll,Joy Conway,Richard W. Costello,Birthe Hellqvist Dahl,Richard Dekhuijzen,Stephen Holmes,Mark L Levy,Mathieu Molimard,Nicholas Roche,Miguel Román-Rodríguez,Nicola Scichilone,Jane Scullion,Omar S. Usmani +15 more
TL;DR: The risk potential for a patient getting switched to a spacer or VHC that delivers a reduced dose medication is discussed, and the performance may vary according to their size, shape, material of manufacture and propensity to become electrostatically charged.